Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: frazierlifesciencesacquisition.com
| Date | Price Target | Rating | Analyst |
|---|
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he
Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
3 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
3 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
10-Q - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
DEFM14A - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
10-Q - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
425 - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)